FI971377A - Adenovirusperäisiä virusvektoreita, joissa on kaksi terapeuttista geeniä: itsemurha- ja immuunistimuloiva geeni - Google Patents

Adenovirusperäisiä virusvektoreita, joissa on kaksi terapeuttista geeniä: itsemurha- ja immuunistimuloiva geeni Download PDF

Info

Publication number
FI971377A
FI971377A FI971377A FI971377A FI971377A FI 971377 A FI971377 A FI 971377A FI 971377 A FI971377 A FI 971377A FI 971377 A FI971377 A FI 971377A FI 971377 A FI971377 A FI 971377A
Authority
FI
Finland
Prior art keywords
suicide
adenovirus
viral vectors
therapeutic genes
derived viral
Prior art date
Application number
FI971377A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI971377A0 (fi
Inventor
Patrice Denefle
Michel Perricaudet
Bruno Tocque
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of FI971377A publication Critical patent/FI971377A/fi
Publication of FI971377A0 publication Critical patent/FI971377A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI971377A 1994-10-04 1997-04-03 Adenovirusperäisiä virusvektoreita, joissa on kaksi terapeuttista geeniä: itsemurha- ja immuunistimuloiva geeni FI971377A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9411846A FR2725213B1 (fr) 1994-10-04 1994-10-04 Vecteurs viraux et utilisation en therapie genique
PCT/FR1995/001274 WO1996010642A1 (fr) 1994-10-04 1995-10-02 Adenoviraux comprenant deux genes therapeutiques: suicide et immunostimulant

Publications (2)

Publication Number Publication Date
FI971377A true FI971377A (fi) 1997-04-03
FI971377A0 FI971377A0 (fi) 1997-04-03

Family

ID=9467551

Family Applications (1)

Application Number Title Priority Date Filing Date
FI971377A FI971377A0 (fi) 1994-10-04 1997-04-03 Adenovirusperäisiä virusvektoreita, joissa on kaksi terapeuttista geeniä: itsemurha- ja immuunistimuloiva geeni

Country Status (9)

Country Link
EP (1) EP0784691A1 (fr)
JP (1) JPH10506289A (fr)
AU (1) AU714867B2 (fr)
CA (1) CA2200629A1 (fr)
FI (1) FI971377A0 (fr)
FR (1) FR2725213B1 (fr)
MX (1) MX9702078A (fr)
NO (1) NO319893B1 (fr)
WO (1) WO1996010642A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960701988A (ko) * 1993-04-20 1996-03-28 윌리엄 에스. 로빈슨 세포내 감염원에 감염된 개체의 치료방법 및 치료물질(methods and materials for treatment of individuals infected with intracellular in-fectious agents)
US6593456B1 (en) 1996-11-06 2003-07-15 The Regents Of The University Of California Tumor necrosis factor receptor releasing enzyme
KR20080009171A (ko) * 1997-08-13 2008-01-24 더 유에이비 리서치 파운데이션 유전자 벡터의 국소 적용에 의한 백신접종
AUPO856097A0 (en) * 1997-08-14 1997-09-04 Commonwealth Scientific And Industrial Research Organisation Vector
US6087164A (en) * 1997-10-03 2000-07-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
US7041654B2 (en) 1997-10-03 2006-05-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
US7569217B2 (en) 2001-09-24 2009-08-04 University Of Saskatchewan Porcine adenovirus E1 and E4 regions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0275300B1 (fr) * 1986-08-01 1996-01-03 Commonwealth Scientific And Industrial Research Organisation Vaccin recombinant
WO1993010218A1 (fr) * 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vecteurs comprenant des genes etrangers et des marqueurs selectifs negatifs
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP0637966B1 (fr) * 1992-05-01 1997-08-27 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Therapie antitumorale a "effet spectateur"
EP0911413A3 (fr) * 1992-12-03 2000-11-15 Genzyme Corporation Vecteur adénoviral minimal pour la thérapie génique
FR2704234B1 (fr) * 1993-04-22 1995-07-21 Centre Nat Rech Scient Virus recombinants, preparation et utilisation en therapie genique.
FR2705361B1 (fr) * 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
WO1995000655A1 (fr) * 1993-06-24 1995-01-05 Mc Master University Vecteurs a base d'adenovirus destines a la therapie genique
FR2707664B1 (fr) * 1993-07-13 1995-09-29 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2712603B1 (fr) * 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.

Also Published As

Publication number Publication date
AU3611495A (en) 1996-04-26
CA2200629A1 (fr) 1996-04-11
FR2725213A1 (fr) 1996-04-05
NO319893B1 (no) 2005-09-26
AU714867B2 (en) 2000-01-13
FR2725213B1 (fr) 1996-11-08
NO971521L (no) 1997-04-03
NO971521D0 (no) 1997-04-03
WO1996010642A1 (fr) 1996-04-11
MX9702078A (es) 1997-06-28
FI971377A0 (fi) 1997-04-03
EP0784691A1 (fr) 1997-07-23
JPH10506289A (ja) 1998-06-23

Similar Documents

Publication Publication Date Title
CZ63995A3 (en) Virus vectors and their use in gene therapy
ZA963434B (en) Gene therapy using replication competent targeted adenoviral vectors.
EP1019028A4 (fr) PROTEINE DE $i(CHLAMYDIA), SEQUENCE GENIQUE, ET UTILISATIONS CORRESPONDANTES
FR2707664B1 (fr) Vecteurs viraux et utilisation en thérapie génique.
WO1996007734A3 (fr) Adenovirus recombine comprenant une proteine chimerique a base pentonique
CA2213343A1 (fr) Proteine fibreuse chimere d'adenovirus et ses procedes d'utilisation
FR2712603B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
FR2725726B1 (fr) Vecteurs viraux et utilisation en therapie genique
FR2718150B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
IT1291135B1 (it) Vettori ricombinanti utilizzabili in terapia genica
FR2712602B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
HUP0104825A3 (en) Genes and proteins, and their use
FI971377A0 (fi) Adenovirusperäisiä virusvektoreita, joissa on kaksi terapeuttista geeniä: itsemurha- ja immuunistimuloiva geeni
CA2278808A1 (fr) Procedes pour la culture de cellules et la multiplication de virus
NO974179L (no) Rekombinante viruser som uttrykker lecitin-kolesterol-acyltransferase, og anvendelse derav i genterapi
NO974726D0 (no) Glucose-induktibel, rekombinant, viral vektor
FR2717495B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
NO20004648L (no) Nukleinsyreoverføringsvektorer, deres anvendelse samt preparater inneholdende vektorene
AU2176997A (en) Novel fused protein, gene therefor, recombinant vector, recombinant virus, and its use
FR2718749B1 (fr) Vecteurs viraux et utilisation en thérapie génique.
PL343000A1 (en) Novel sequence class of genes, corresponding proteins and the use of the same
GB9824569D0 (en) Virulence gene and protein,and their use
AU6000500A (en) Virus vectors and preparations and their uses
FR2717823B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
AP2005003413A0 (en) Genes and proteins, and their use.

Legal Events

Date Code Title Description
MA Patent expired